Affimed validates antibody target for cancer metastasis
Affimed Therapeutics AG announced that a collaboration with Dr. Stefan Weiss at the Institute of biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic interventions. The target, 37 kDa/67 kDa laminin receptor precursor and/ or its receptor, is overexpressed in cancer cell lines and their metastatic potential correlates with LRP/LR levels. Affimed was able to demonstrate that an antibody targeting this receptor could reduce invasive potential by up to 40% and adhesion by up to 70%.
LRP/LR acts as a receptor for prions and viruses, but has also been shown to be overexpressed in metastatic cancer tissue. In the present study, it was challenged in a metastatic cancer cell line with a variety of therapeutic strategies including single chain and full IgG antibodies, siRNAs and small molecules (polysulfated glycanes).The effects on the invasive and adhesive properties of the cells were examined using in vitro models of cell migration. Invasion and adhesion are the processes by which cancer cells metastasize and spread to multiple other regions of the body. The single chain and full length antibodies were able to reduce invasion by 30% and 40%, respectively, and adhesion by 60% and 70%, respectively.
Prof. Melvyn Little, CSO of Affimed commented: "Our data suggest that reagents directed against LRP/LR, in particular antibodies, might be potential cancer therapeutics blocking metastases. Once again we have been able to demonstrate Affimed's competence in generating new, fully human antibodies against innovative targets."
Original publication: Zuber, C., Knackmuss, S., Zemora , G., Reusch, U., Vlasova, E., Diehl, D., Mick , V., Hofmann, K., Nikles, D., Fröhlich, T., Arnold, G., Brenig, B., Wolf, E., Lahm, H., Little, M., & Weiss, S.; "Invasion of tumorigenic HT1080 cells is impeded by blocking or downregulating the 37 kDa/67 kDa laminin receptor."; Journal of Molecular Biology 2008, Volume 378, Issue 3, Pages 530-539.
Other news from the department research and development
These products might interest you

Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation

DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference

CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy

Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines

DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection

Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous